HNC664

HNC664 is an orally administered small molecule drug candidate developed by Guangzhou Henovcom Bioscience (also referenced as Guangzhou Koncen Bioscience) for the treatment of advanced solid tumors, with a primary focus on pancreatic cancer. Its mechanism of action is as an autotaxin inhibitor, targeting the enzyme autotaxin to potentially disrupt tumor progression. The drug has been evaluated in Phase 1 clinical trials both as monotherapy and in combination with gemcitabine and albumin-bound paclitaxel for patients with locally advanced or metastatic pancreatic cancer. Additional studies have assessed its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy subjects[1][2][3][4][5][7].